Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04343573
Other study ID # 20-117
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date April 10, 2020
Est. completion date April 2025

Study information

Verified date May 2024
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators are doing this study to find out whether proton craniospinal radiation therapy (proton CSI) or partial photon radiation therapy is more effective at preventing leptomeningeal metastasis from worsening. The proton CSI targets the entire space containing the CSF, brain, and spinal fluid. The partial photon radiation therapy treats only areas where the patient is having symptoms, such as the entire brain or part of the spine. The investigators also want to find out if proton CSI improves the symptoms patients may be experiencing because of the leptomeningeal metastasis. In addition, the investigators will compare the side effects of proton CSI and partial photon therapy. Patients undergoing proton beam RT will receive their treatment at the New York Proton Center in New York, NY. As part of the New York Proton Consortium, MSK has contracted for its faculty to treat patients at the New York Proton Center. If it is unfeasible for patients to get treated at NYPC, patients will have the decision to get treated at ProCure in Summerset, NJ.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 102
Est. completion date April 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group N/A to 99 Years
Eligibility Inclusion Criteria: - Patient with solid tumor malignancy with leptomeningeal metastases established radiographically and/or through CSF cytology - Patients who are candidates for radiation therapy for the treatment of leptomeningeal metastases - Patients of all ages - KPS = 60 for participants = 16 years old, and Lansky = 60 for participants < 16 years old - For adult patient, the patient/ legally authorized representative is able to provide informed consent. For pediatric patient, a parent is able to provide informed consent. - Adequate bone marrow function: - Hemoglobin > 8g/dL - Absolute neutrophil count >1,000/mm - Platelet count > 100,000/mm - Female subjects must either be of non-reproductive potential (i.e. pediatric patients, OR postmenopausal by history [= 60 years old, or with no menses for >1 year without an alternative medical cause], OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test within 2 weeks prior to starting treatment. - Patient at reproductive potential must agree to practice an effective contraceptive method. Exclusion Criteria: - Patient with multiple, serious major neurologic deficits per physician/investigator assessment including encephalopathy - Patient with extensive systemic disease and without reasonable systemic treatment options - Patient who is unable to undergo MRI brain and spine with gadolinium contrast - Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances - Pregnant or lactating women.

Study Design


Intervention

Radiation:
Involved-field Photon Radiation Therapy
Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions)
Proton Craniospinal Irradiation (CSI)
Proton CSI (30Gy [RBE] in 10 fractions)
Other:
Neurocognitive Assessment
All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT. The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available. Patients will also complete self-report mood and fatigue scales at each of the same time points. This testing will only be done at MSKCC. Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments. Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
MDASI-BT and MDASI-SP
Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression. Only one set needs to be completed. Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available. Questionnaires will be completed via mail, in-person, or online (MSK Engage).

Locations

Country Name City State
United States Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey
United States Memorial Sloan Kettering Commack (Limited Protocol Activities) Commack New York
United States Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York
United States Memorial Sloan Kettering Monmouth (Limitedl protocol activities) Middletown New Jersey
United States Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center New York New York
United States Memorial Sloan Kettering Nassau (Limited Protocol Activities) Uniondale New York

Sponsors (2)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Fred Hutchinson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary CNS progression free survival For Arm A and Arm B, which will be defined as the duration of time from the date of randomization to the time of progression of disease or death, whichever occurs first. The baseline imaging study will be the diagnostic imaging obtained at study entry. 2 years
Secondary overall survival (OS) (Arm A and Arm B) will be included in an analysis of overall survival, defined as time from randomization to death. 2 years
See also
  Status Clinical Trial Phase
Withdrawn NCT01438021 - Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease N/A
Completed NCT02616393 - Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases Phase 2
Completed NCT03101579 - Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer Phase 1
Not yet recruiting NCT06462092 - Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT03719768 - Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Phase 1
Terminated NCT00005812 - Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma Phase 2
Terminated NCT03661424 - BATs in Patients With Breast Cancer and Leptomeningeal Metastases Phase 1
Active, not recruiting NCT05289908 - Intrathecal Pemetrexed for Leptomeningeal Metastasis Phase 1/Phase 2
Recruiting NCT05184816 - A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis Phase 1
Not yet recruiting NCT03613181 - ANG1005 in Leptomeningeal Disease From Breast Cancer Phase 3
Terminated NCT03275402 - 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases Phase 2/Phase 3
Completed NCT01645839 - Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer Phase 3
Completed NCT03520504 - Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases Phase 1
Completed NCT00992602 - Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer Phase 2
Completed NCT00005811 - Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment Phase 2